Veru Inc (VERU) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.42 (+1.26%), Market cap $0.03B, 52-week low–high $0.37 ~ $4.43.
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microt
Financial statements, price targets, institutional (13F) holdings and related news for Veru Inc are updated in real time on BlackAll Trade.
Veru Inc trades at $2.42 (+1.26%). Real-time quotes and charts are available on BlackAll Trade.
Veru Inc has a market cap of about $0.03B.
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS)